Biological therapy of ovarian cancer

doi:10.3760/cma.j.issn.1673-422X.2013.11.018

Abstract

Abstract: In recent years, the biological therapy of ovarian cancer has made great progress. Immunotherapy including tumor vaccine and adoptive immunity cell therapy can improve immune recognition capability, while the applications of molecular targeted drugs such as monoclonal antibodies and tyrosine kinase inhibitors for different target spots during the tumor cells growth progresses achieve significant clinical benefit, as well as hormone replacement therapy and Chinese medicine treatment improve the life quality of patients with ovarian cancer to a certain degree.

Key words: Ovarian neoplasms, Immunotherapy, Molecular targeted therapy

XU Hui-Ru, FENG Hui-Jing, ZHANG Jun-Ping. Biological therapy of ovarian cancer[J]. Journal of International Oncology, 2013, 40(11): 861-864.

References

［1］ Tanyi JL, Chu CS. Dendritic cellbased tumor vaccinations in epithelial ovarian cancer: a systematic review. Immunotherapy, 2012, 4(10): 995-1009. ［2］程志勇. DC-CIK在卵巢癌治疗中的疗效观察. 中国医药指南, 2012, 10 (14):149-150. ［3］桑圣刚, 荣红. DC-CIK细胞治疗对晚期卵巢癌患者外周血CK19-mRNA表达的影响. 海南医学院学报, 2012,18(5):610-613. ［4］Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med, 2011, 365(26):2484-2496. ［5］Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med, 2011, 365(26):2473-2483. ［6］Garcia AA, Hirte H, Fleming G, et al. Phase Ⅱ clinical trial of bevacizumab and lowdose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California，Chicago，and Princess Margaret Hospital phaseⅡ consortia．J Clin Oncol, 2008, 26(1):76-82. ［7］Heitz F, Harter P, Barinoff J, et al． Bevacizumab in the treatment of ovarian cancer. Adv Ther， 2012,29(9):723-735. ［8］Siwak DR, Carey M, Hennessy BT, et al. Targeting the epidermal growth facter receptor in epithelial ovrian cancer: current knowledge and future chanllenges. J Oncol, 2009, 69(1):1-20. ［9］Secord AA, Blessing JA, Armstrong DK, et al. Phase Ⅱ trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study. Gynecol Oncol, 2008, 108(3):493-499．［10］Schilder RJ, Pathak HB, Lokshin AE, et al. Phase Ⅱ trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gynecol Oncol, 2009, 113(1):21-27. ［11］Pautier P, Joly F, Kerbrat P, et al. Phase Ⅱ study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma(1839IL/0074). Gynecol Oncol, 2010, 116(2):157-162. ［12］Vasey PA, Gore M, Wilson R, et al. A phase Ⅰb trial of docetaxel，carboplatin and erlotinib in ovarian，fallopian tube and primary peritoneal cancers．Br J Cancer, 2008, 98(11):1774-1780. ［13］Kimball KJ, Numnum TM, Kirby TO, et al. A phase Ⅰ study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma. Gynecol Oncol, 2008, 111(1):95-101. ［14］Weroha SJ, Oberg AL, Ziegler KL, et al. Phase Ⅱ trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma. Gynecol Oncol, 2011,122(1): 116-120. ［15］Armstrong DK, White AJ, Weil SC, et al. Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovariancancer. Gynecol Oncol, 2013, 129(3):452-458. ［16］Bodnar L, Gornas M, Szczylik C. Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer：a phase Ⅱ study. Gynecol Oncol, 2011, 123（1）：33-36. ［17］WilkinsonRyan I, Mutch D. A review of iniparib in ovarian cancer. Expert Opin Investig Drugs, 2013, 22(3):399-405. ［18］Reyners AK, de Munck L, Erdkamp FL, et al. A randomized phase Ⅱ study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage ⅠC to Ⅳ epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study. Ann Oncol, 2012, 23(11):2896-2902. ［19］ Murdoch WJ, Van Kirk EA, Isaak DD, et al. Progesterone facilitates cisplatin toxicity in epithelial ovarian cancer cells and xenografts．Gynecol Oncol, 2008, 110(2):251-255．［20］Psyrri A, Kountourakis P, Yu Z, et al. Analysis of p53 protein expression levels on ovarian cancer tissue microarray using automated quantitative analysis elucidates prognostic patient subsets. Ann Oncol, 2007, 18(4):709-715．

[1]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[2]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[3]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[4]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[5]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[6]	Wang Peixin, Zhao Jun, Xu Shihong, Jiang Zhaoyang, Wang Xiaoqiang, Yang Hongjuan. Progress of ferroptosis-related mechanisms in osteosarcoma [J]. Journal of International Oncology, 2024, 51(5): 308-311.
[7]	Yang Hao, Shi Guidong, Zhang Chengcheng, Zhang Yue, Zhang Liwen, Fu Maoyong. Comparison of efficacy and safety between sintilimab and tislelizumab in neoadjuvant therapy for advanced esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(4): 210-216.
[8]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[9]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[10]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150.
[11]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.
[12]	Gong Yan, Chen Honglei. Research progress on the mechanism of microRNA regulation of cisplatin resistance in ovarian cancer [J]. Journal of International Oncology, 2024, 51(3): 186-190.
[13]	Cui Tenglu, Lyu lu, Sun Pengfei. Application of radiotherapy combined with immunotherapy in the treatment of head and neck squamous cell carcinoma [J]. Journal of International Oncology, 2023, 50(9): 548-552.
[14]	Huang Hui, Ding Jianghua. Advances in targeting FGFR2 for treatment of advanced cholangiocarcinoma [J]. Journal of International Oncology, 2023, 50(9): 569-573.
[15]	An Rong, Liu Meihua, Wang Peichen, Wang Xiaohui. Research progress of Nrf2 in ovarian cancer [J]. Journal of International Oncology, 2023, 50(8): 493-497.